In the next few weeks, we can expect Fiscal 2022 results from Bloom Health Partners (CSE: BLMH). These results are expected to be a huge catalyst, as the company is well on track to beat yearly guidance of $25-$28 million.
Fiscal Q3 revenue brought BLMH’s YTD revenues to $24.9 million. If the company’s Fiscal Q4 performance remains strong, it is well on track to achieve well over $30 million in yearly revenues. This will put the company at a P/S ratio of around .28. For comparison, the average P/S ratio for other companies in BLMH’s sector is ~4. This means BLMH should theoretically be trading at a valuation of $120-$132 million.
BLMH recently expanded its operations to Hawaii to serve film/TV productions in addition to new opportunities with local businesses and organizations in the surrounding area. This new development should guarantee strong quarterly performance from BLMH.
BLMH.c is currently trading at $.19, valued at $9.06 million.
https://ceo.ca/@newsfile/bloom-health-partners-announces-new-location-in-hawaii